Search By Initial

Name Index P

• Panobinostat (Catalog# : 17022809, Cas# : 404950-80-7)Panobinostat(LBH-589) is a broad-spectrum HDAC inhibitor; low nanomolar concentration
• Pelitinib (Catalog# : 17022702, Cas# : 257933-82-7)Pelitinib (EKB-569; WAY-EKB 569) is a potent irreversible EGFR inhibitor with IC50 of
• PCI-34051 (Catalog# : 17022402, Cas# : 950762-95-5)PCI-34051 is a potent, histone deacetylase 8 (HDAC8)-specific inhibitor with >200-fol
• Psoralen (Catalog# : 17021307, Cas# : 66-97-7)Psoralen is a naturally occurring furocoumarin that intercalates with DNA, inhibiting
• P7C3-A20 (Catalog# : 16122838, Cas# : 1235481-90-9)P7C3-A20 is an analogue of P7C3, and is a proneurogenic, neuroprotective agent. P7C3-
• P7C3 (Catalog# : 16122837, Cas# : 301353-96-8)P7C3 is a proneurogenic, neuroprotective agent. P7C3 protects newborn neurons from ap
• 3PO (Catalog# : 161227109, Cas# : 13309-08-5)3PO is a PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor. 3PO
• P5091 (P005091) (Catalog# : 16122795, Cas# : 882257-11-6)P5091(P005091) is a selective and potent inhibitor of ubiquitin-specific protease 7 (
• PYR-41 (Catalog# : 16122793, Cas# : 418805-02-4)PYR-41 is the first cell-permeable inhibitor of ubiquitin-activating enzyme E1, with
• PRI-724 (Catalog# : 16122785, Cas# : 847591-62-2)PRI-724 is a potent, specific inhibitor of the canonical Wnt signaling pathway in can
• PLX7904 (Catalog# : 16122777, Cas# : 1393465-84-3)PLX7904, also known as PB04, is a potent and selective paradox-breaker RAF inhibitor.
• Pamapimod (R-1503, Ro4402257) (Catalog# : 16122774, Cas# : 449811-01-2)Pamapimod (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activate
• PRIMA-1 (Catalog# : 16122770, Cas# : 5608-24-2)PRIMA-1 is a mutant p53 reactivator. It induces apoptosis and inhibits growth of huma
• Picolinamide (Catalog# : 16122714, Cas# : 1452-77-3)Picolinamide is found to be a strong inhibitor of poly (ADP-ribose) synthetase of nuc
• PD0166285 (Catalog# : 16122710, Cas# : 185039-89-8)PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentratio
• Peficitinib (ASP015K, JNJ-54781532) (Catalog# : 16122707, Cas# : 944118-01-8)Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
• PF-543 Citrate (Catalog# : 6111525, Cas# : 1415562-83-2)PF-543 Citrate is a novel cell-permeant inhibitor of SphK1 with a K(i) of 3.6 nM, PF-
• Pasireotide (Catalog# : 61115, Cas# : 396091-73-9)Pasireotide(SOM 230) is a stable cyclohexapeptide somatostatin mimic that exhibits un
• PFI-3 (Catalog# : 6111020, Cas# : 1819363-80-8)PFI-3
• PF-2771 (Catalog# : 611943)PF-2771 is a potent, selective CENP-E inhibitor, PF-2771 inhibits CENP-E motor activi
• PF-04929113 Mesylate (Catalog# : 611939, Cas# : 1173111-67-5)PF-04929113 Mesylate is a potent and selective Hsp90 inhibitor with an IC50 of median
• PI4KIIIbeta-IN-9 (Catalog# : 611908, Cas# : 1429624-84-9)PI4KIII-IN-9 is a potent PI4KIII inhibitor (IC50 of 7 nM) and is >140-fold selecti
• PI4KIIIbeta-IN-10 (Catalog# : 611907, Cas# : 1881233-39-1)PI4KIIIbeta-IN-10 is the most potent PI4KIII inhibitor currently reported, with very
• PI3Kα inhibitor 1 (Catalog# : 611903, Cas# : 1235449-52-1)PI3Kα inhibitor 1 is a PI3Kα inhibitor extracted from patent US/20120088764A1, comp
• PF-04979064 (Catalog# : 611902, Cas# : 1220699-06-8)PF-04979064 is a potent and selective PI3K/mTOR dual kinase inhibitor with an IC(50)
• PQR620 (Catalog# : 611821, Cas# : 1927857-56-4)PRQ620 is a highly potent and selective mTORC1/2 inhibitor, shows anti-tumor effects
• PP121 (Catalog# : 161009011, Cas# : 1092788-83-4)PP121 blocks the proliferation of tumor cells by direct inhibition of oncogenic tyros
• PF-4989216 (Catalog# : 161009002, Cas# : 1276553-09-3)PF-4989216 inhibits the phosphorylation of PI3K downstream molecules and subsequently
• PIK-294 (Catalog# : 160926013, Cas# : 900185-02-6)PIK-294 is a highly selective inihibitor of the phosphoinositide 3-kinase (PI3K) p110
• PIK-90 (Catalog# : 160926010, Cas# : 677338-12-4)PIK-90 is a potent PI3K inhibitor with potential anticancer activity.